Cargando…
Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience
Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535840/ https://www.ncbi.nlm.nih.gov/pubmed/34683075 http://dx.doi.org/10.3390/healthcare9101395 |
_version_ | 1784587880959574016 |
---|---|
author | Sawada, Kiyoka Nakayama, Kentaro Nakamura, Kohei Yoshimura, Yuki Razia, Sultana Ishikawa, Masako Yamashita, Hitomi Ishibashi, Tomoka Sato, Seiya Kyo, Satoru |
author_facet | Sawada, Kiyoka Nakayama, Kentaro Nakamura, Kohei Yoshimura, Yuki Razia, Sultana Ishikawa, Masako Yamashita, Hitomi Ishibashi, Tomoka Sato, Seiya Kyo, Satoru |
author_sort | Sawada, Kiyoka |
collection | PubMed |
description | Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examine the efficacy and clinical feasibility of genotype-matched therapy. Target sequencing was performed in 20 cases of gynecological cancers (cervical cancer, 6; endometrial cancer, 6; and ovarian cancer, 6). Both actionable and druggable genes were identified in 95% (19/20) of the cases. Among them, seven patients (35%) received genotype-matched therapy, which was effective in three patients. Of the three patients, one patient with a PTEN mutation received everolimus, another patient with a TSC2 mutation received everolimus and letrozole, and the patient with a BRIP1 mutation received olaparib. Subsequently, disease control in these three patients lasted for more than half a year. However, all patients relapsed between 9 and 13 months after the initiation of genotype-matched therapy. In this study, the response rate of genotype-matched therapy was 43% (3/7), which may have contributed to improved prognoses. Therefore, genotype-matched therapies may help patients with refractory gynecological cancers achieve better outcomes. |
format | Online Article Text |
id | pubmed-8535840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85358402021-10-23 Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience Sawada, Kiyoka Nakayama, Kentaro Nakamura, Kohei Yoshimura, Yuki Razia, Sultana Ishikawa, Masako Yamashita, Hitomi Ishibashi, Tomoka Sato, Seiya Kyo, Satoru Healthcare (Basel) Article Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examine the efficacy and clinical feasibility of genotype-matched therapy. Target sequencing was performed in 20 cases of gynecological cancers (cervical cancer, 6; endometrial cancer, 6; and ovarian cancer, 6). Both actionable and druggable genes were identified in 95% (19/20) of the cases. Among them, seven patients (35%) received genotype-matched therapy, which was effective in three patients. Of the three patients, one patient with a PTEN mutation received everolimus, another patient with a TSC2 mutation received everolimus and letrozole, and the patient with a BRIP1 mutation received olaparib. Subsequently, disease control in these three patients lasted for more than half a year. However, all patients relapsed between 9 and 13 months after the initiation of genotype-matched therapy. In this study, the response rate of genotype-matched therapy was 43% (3/7), which may have contributed to improved prognoses. Therefore, genotype-matched therapies may help patients with refractory gynecological cancers achieve better outcomes. MDPI 2021-10-19 /pmc/articles/PMC8535840/ /pubmed/34683075 http://dx.doi.org/10.3390/healthcare9101395 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sawada, Kiyoka Nakayama, Kentaro Nakamura, Kohei Yoshimura, Yuki Razia, Sultana Ishikawa, Masako Yamashita, Hitomi Ishibashi, Tomoka Sato, Seiya Kyo, Satoru Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience |
title | Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience |
title_full | Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience |
title_fullStr | Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience |
title_full_unstemmed | Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience |
title_short | Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience |
title_sort | clinical outcomes of genotype-matched therapy for recurrent gynecological cancers: a single institutional experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535840/ https://www.ncbi.nlm.nih.gov/pubmed/34683075 http://dx.doi.org/10.3390/healthcare9101395 |
work_keys_str_mv | AT sawadakiyoka clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT nakayamakentaro clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT nakamurakohei clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT yoshimurayuki clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT raziasultana clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT ishikawamasako clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT yamashitahitomi clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT ishibashitomoka clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT satoseiya clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience AT kyosatoru clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience |